COCH Stock Overview
Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Envoy Medical, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.18 |
52 Week High | US$11.72 |
52 Week Low | US$0.75 |
Beta | 2.66 |
1 Month Change | 32.48% |
3 Month Change | 283.70% |
1 Year Change | -48.30% |
3 Year Change | -46.87% |
5 Year Change | n/a |
Change since IPO | -46.93% |
Recent News & Updates
Recent updates
Shareholder Returns
COCH | US Medical Equipment | US Market | |
---|---|---|---|
7D | 2.4% | 1.6% | 1.0% |
1Y | -48.3% | -1.4% | 21.9% |
Return vs Industry: COCH underperformed the US Medical Equipment industry which returned -1.4% over the past year.
Return vs Market: COCH underperformed the US Market which returned 21.9% over the past year.
Price Volatility
COCH volatility | |
---|---|
COCH Average Weekly Movement | 59.7% |
Medical Equipment Industry Average Movement | 7.3% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: COCH's share price has been volatile over the past 3 months.
Volatility Over Time: COCH's weekly volatility has increased from 38% to 60% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1995 | 34 | Brent Lucas | www.envoymedical.com |
Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023.
Envoy Medical, Inc. Fundamentals Summary
COCH fundamental statistics | |
---|---|
Market cap | US$101.53m |
Earnings (TTM) | -US$29.91m |
Revenue (TTM) | US$316.00k |
321.3x
P/S Ratio-3.4x
P/E RatioIs COCH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
COCH income statement (TTM) | |
---|---|
Revenue | US$316.00k |
Cost of Revenue | US$789.00k |
Gross Profit | -US$473.00k |
Other Expenses | US$29.44m |
Earnings | -US$29.91m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -1.53 |
Gross Margin | -149.68% |
Net Profit Margin | -9,464.56% |
Debt/Equity Ratio | 0% |
How did COCH perform over the long term?
See historical performance and comparison